- Home
- PFS vs DNLI Comparison
PFS vs DNLI Comparison
Compare PFS & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFS
- DNLI
- Stock Information
- Founded
- PFS 1839
- DNLI 2013
- Country
- PFS United States
- DNLI United States
- Employees
- PFS N/A
- DNLI N/A
- Industry
- PFS Savings Institutions
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFS Finance
- DNLI Health Care
- Exchange
- PFS Nasdaq
- DNLI Nasdaq
- Market Cap
- PFS 2.4B
- DNLI 2.5B
- IPO Year
- PFS N/A
- DNLI 2017
- Fundamental
- Price
- PFS $18.11
- DNLI $17.25
- Analyst Decision
- PFS Strong Buy
- DNLI Strong Buy
- Analyst Count
- PFS 5
- DNLI 13
- Target Price
- PFS $23.00
- DNLI $32.64
- AVG Volume (30 Days)
- PFS 680.0K
- DNLI 1.4M
- Earning Date
- PFS 10-29-2025
- DNLI 11-06-2025
- Dividend Yield
- PFS 5.35%
- DNLI N/A
- EPS Growth
- PFS 100.33
- DNLI N/A
- EPS
- PFS 1.96
- DNLI N/A
- Revenue
- PFS $836,917,000.00
- DNLI N/A
- Revenue This Year
- PFS $30.95
- DNLI N/A
- Revenue Next Year
- PFS $10.41
- DNLI $94,232.03
- P/E Ratio
- PFS $9.15
- DNLI N/A
- Revenue Growth
- PFS 59.19
- DNLI N/A
- 52 Week Low
- PFS $14.34
- DNLI $10.57
- 52 Week High
- PFS $22.24
- DNLI $26.18
- Technical
- Relative Strength Index (RSI)
- PFS 42.13
- DNLI 57.29
- Support Level
- PFS $17.71
- DNLI $16.66
- Resistance Level
- PFS $19.24
- DNLI $18.21
- Average True Range (ATR)
- PFS 0.42
- DNLI 1.06
- MACD
- PFS -0.03
- DNLI 0.12
- Stochastic Oscillator
- PFS 26.71
- DNLI 66.46
About PFS Provident Financial Services Inc
Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.